1. Introduction {#sec1-cells-08-01223}
===============

Inter-cell communication is at the very heart of organism function. As our single-celled ancestors evolved to more and more complex organisms, the development of more specialized, specific, and fine-tuned cellular signaling tools was essential. Many of these long-evolved core systems that control cell survival/growth homeostasis are seized upon in the initiation and the maintenance of the malignant phenotype \[[@B1-cells-08-01223]\]. Among them, the receptor for the insulin-like growth factor 1 (IGF-1R) is one of the most evolved tools. The IGF-1R, the insulin receptor (IR), the insulin-related receptor (IRR) \[[@B2-cells-08-01223]\], and the most recently added IR/IGF-1R hybrid receptor \[[@B3-cells-08-01223],[@B4-cells-08-01223]\] share a common ancestor that can be traced back 600 million years \[[@B5-cells-08-01223],[@B6-cells-08-01223],[@B7-cells-08-01223]\]. This primordial receptor was activated by only one ligand yet orchestrated multiple cellular functions from cell growth and metabolism to proliferation and survival. Somewhere along the evolutionary timeline towards mammals, both the primordial receptor and its singular ligand sustained a series of duplications that led to the development of several specialized receptors and ligands within the insulin/insulin-like growth factor (IIGF) family \[[@B8-cells-08-01223],[@B9-cells-08-01223]\]. In mammals, the IR preferentially binds insulin and is involved in the regulation of cellular metabolism. The IGF-1R preferentially binds IGF-1 and IGF-2, although it can also be activated by insulin, and is implicated mostly in cellular proliferation, differentiation, and survival.

Considering the IGF-1R's key roles in fundamental biological processes, it is not surprising that it is frequently found to be hijacked by awry oncogenic processes \[[@B10-cells-08-01223],[@B11-cells-08-01223],[@B12-cells-08-01223]\]. Extensive experimental and epidemiological studies have thoroughly documented the link between malignancy and IGF-1R across the majority of human cancer types. Not only is IGF-1R expression necessary for malignant transformation by numerous major oncogenes, but receptor inhibition (either by suppressing expression or activation) has been shown to lead to tumor cell growth inhibition \[[@B13-cells-08-01223],[@B14-cells-08-01223],[@B15-cells-08-01223]\]. As such, the IGF system has emerged as an obvious target for cancer therapy, fueling development of several anti-IGF-1R drugs and subsequent clinical trials \[[@B16-cells-08-01223],[@B17-cells-08-01223],[@B18-cells-08-01223],[@B19-cells-08-01223]\]. In light of the structure-centered classification of the IGF-1R as a receptor tyrosine kinase (RTK) (for extensive review, see \[[@B11-cells-08-01223]\]) early in the drug development phase, inhibition of its kinase signaling was deemed the best anti-cancer strategy. To achieve this goal, several small-molecule kinase inhibitors and agents preventing ligand--receptor interaction were developed ([Table 1](#cells-08-01223-t001){ref-type="table"}) \[[@B20-cells-08-01223],[@B21-cells-08-01223]\]. Most of the kinase inhibitors were soon abandoned, as they interfered with cell metabolism by also inhibiting the IR. Within the category of agents preventing ligand--receptor interaction, quite a few anti-IGF-1R antibodies were developed, and their efficacy tested in cell systems by using receptor phosphorylation as the main read-out. The most effective in preventing IGF-1R auto-phosphorylation were selected to be tested in clinical settings, yet in spite of promising preclinical data, clinical trials did not deliver the expected results \[[@B19-cells-08-01223],[@B22-cells-08-01223],[@B23-cells-08-01223]\]. This failure has led the field to question: is the inconsistency between outcomes in clinical and experimental settings a result of drug ineffectiveness or ultimately the wrong target? \[[@B10-cells-08-01223],[@B17-cells-08-01223],[@B19-cells-08-01223],[@B22-cells-08-01223]\].

It was proposed more than a decade ago that IGF-1R downregulation (i.e., removal of the receptor from the cell surface) was a pre-requisite for any knock-on anti-neoplastic effects \[[@B13-cells-08-01223],[@B24-cells-08-01223],[@B25-cells-08-01223]\] and hence, the concept of receptor downregulation began to look more and more like the missing piece of the IGF-1R targeting puzzle. In this review, we examine IGF-1R downregulation and endocytosis as related to the rise and fall of IGF-1R targeted cancer therapy \[[@B22-cells-08-01223]\].

2. Receptor Internalization: The RTK Route {#sec2-cells-08-01223}
==========================================

RTK endocytosis, i.e., the internalization and the trafficking of receptors inside the cell, was long believed to solely serve to terminate RTK signaling. However, more recent studies have demonstrated that RTKs actually continue to signal along the endocytic pathway. Hence, it is acknowledged today that the endocytic platform acts more as a master-regulatory device governing the spatio-temporal signaling, the distribution, and ultimately the biological outcome.

Plasma membrane receptors start their life-span synthesized in the endoplasmic reticulum and are then transported through the Golgi apparatus and delivered to the plasma membrane. Here, mature receptors accumulate, primed for their function to sense the extra-cellular environment. Eventually, plasma membrane receptors undergo endocytosis (internalization), by which they re-enter the cell, pass through the acidic endosomal system, and are processed for either recycling (returned to the plasma membrane) or undergo lysosomal or proteosomal degradation. Some degree of basal turnover is likely to go on with all receptors, which is thought to maintain receptor homeostasis at the plasma membrane. Some receptors internalize independently of a ligand (e.g., the transferrin receptor) \[[@B60-cells-08-01223],[@B61-cells-08-01223],[@B62-cells-08-01223]\]; however, receptor internalization is primarily ligand-dependent. Constitutive (ligand-independent) receptor endocytosis is a slow process and occurs at a similar rate to other membrane proteins \[[@B63-cells-08-01223]\]. Altogether, the rates of constitutive internalization, recycling, and degradation determine the half-life of an RTK and can vary greatly depending on receptor, cell type, and patho-physiological condition. For example, the half-life of the colony stimulating factor 1 receptor (CSF-1R) in macrophages is less than 1 h \[[@B64-cells-08-01223],[@B65-cells-08-01223]\], whereas for the epidermal growth factor receptor (EGFR) in carcinoma cells, it is 24 h \[[@B66-cells-08-01223]\]. The IIGF family receptors are likely somewhere in the middle, with estimates around 6--7 h \[[@B67-cells-08-01223]\]. Canonical internalization of RTKs occurs after the binding of their respective ligands. Ligand binding causes auto-phosphorylation of the RTK intracellular tyrosine kinase domain as well as activation of the internalization signals (e.g., the conjugation of ubiquitin), allowing recruitment of adaptor molecules for the endocytosis machinery. For this reason, RTK internalization is often recognized as being coupled to kinase activation; ligand binding initiates both processes, greatly intensifying internalization rates, and is ultimately responsible for the downregulation of RTK populations \[[@B68-cells-08-01223],[@B69-cells-08-01223],[@B70-cells-08-01223]\].

2.1. Receptor Ubiquitination {#sec2dot1-cells-08-01223}
----------------------------

Originally believed to serve as a label for protein degradation, it is now well accepted that the ubiquitin tagging of receptors serves as a sorting signal that directs subcellular trafficking. Ubiquitination is the covalent attachment of a 7 kDa ubiquitin polypeptide to lysine residues of a target protein. This process is orchestrated by the sequential action of E1, E2, and E3 ligase enzymes \[[@B71-cells-08-01223]\]. E1 and E2 load E3 with the ubiquitin, and E3 transfers it to the target protein and hence provides substrate specificity \[[@B72-cells-08-01223]\]. Proteins can be mono-ubiquitinated (addition of a single ubiquitin moiety), multi-ubiquitinated (at multiple lysine residues), or poly-ubiquitinated (addition of ubiquitin chains) \[[@B73-cells-08-01223],[@B74-cells-08-01223]\]. Poly-ubiquitination can occur in a straight chain or branched, depending on which of the lysine residues within one ubiquitin molecule the subsequent ubiquitin molecule is attached to. Old or damaged cytosolic proteins are labeled with a poly-ubiquitin chain, which is then recognized and degraded by the proteasome constructed of multi-subunit proteolytic enzymes situated in the cytoplasm. In addition to the degradation of cytosolic proteins, ubiquitination tagging serves as a barcode to dictate the trafficking and the ultimate fate of the RTK through endosomal sorting. All major RTK subtypes are ubiquitinated upon growth factor stimulation. They can be mono-ubiquitinated or poly-ubiquitinated, and the type of modification regulates their ensuing fate \[[@B11-cells-08-01223],[@B74-cells-08-01223]\].

Ubiquitin conjugation sites have been mapped within the IGF-1R, and mutational analysis studies have characterized their roles in subcellular trafficking \[[@B11-cells-08-01223],[@B69-cells-08-01223],[@B75-cells-08-01223],[@B76-cells-08-01223]\]. Sepp-Lorenzino et al. \[[@B77-cells-08-01223]\] described IGF-1R degradation by a proteasome-mediated route in order to explain Herbymicin A-induced IGF-1R downregulation. Herbymicin A promoted IGF-1R degradation only in the presence of a functional ubiquitin E1 enzyme. Further, its action was prevented by proteasome inhibitors but insensitive to lysosomal inhibitors. Since then, four distinct E3 ubiquitin ligases have been recognized to promote IGF-1R ubiquitination and its subsequent degradation: Mdm2 \[[@B76-cells-08-01223]\], Nedd4 \[[@B78-cells-08-01223]\], c-Cbl \[[@B79-cells-08-01223]\], and HRD1 \[[@B80-cells-08-01223]\]. This complexity suggests a function-dependency to the ubiquitination processing \[[@B68-cells-08-01223]\]. The majority of reports thus far indicate that ubiquitination of the IGF-1R is mostly a ligand-dependent process---stimulation with IGF-1 rapidly induces receptor ubiquitination (within 5 min) with subsequent endocytosis. This can be seen on a receptor population level after about 6 h as detectably lower IGF-1R expression levels in whole cell lysates \[[@B69-cells-08-01223],[@B79-cells-08-01223]\]. To unpick the interplay between the E3 ubiquitin ligases, Sehat et al. reported that low doses of IGF-1 (5 ng/mL) led to Mdm2-mediated ubiquitination, whereas high doses (50--100 ng/mL) led to c-Cbl-mediated receptor ubiquitination \[[@B79-cells-08-01223]\]. Mechanistically, Mdm2 and c-Cbl are RING-type E3 ligases, making them capable of acting alone, whereas Nedd4 is a HECT E3 ubiquitin ligase. However, it has been demonstrated that Mdm2 and Nedd4 bind the IGF-1R via the adaptor proteins β-arrestin \[[@B81-cells-08-01223],[@B82-cells-08-01223]\] and Grb 10 \[[@B83-cells-08-01223]\], respectively. Such additional control layers suggest that the adaptor proteins may determine substrate specificity \[[@B68-cells-08-01223]\].

The placement and the arrangement of ubiquitin molecules encodes instructions for further receptor processing. Mdm2 has been shown to attach K63-conjugated ubiquitin chains, whereas c-Cbl attached K48-conjugated ubiquitin chains \[[@B79-cells-08-01223]\]. This divergence can then be followed in the subsequent internalization routes and receptor fate \[[@B68-cells-08-01223]\].

2.2. Clathrin-Dependent and Independent Receptor Internalization {#sec2dot2-cells-08-01223}
----------------------------------------------------------------

Ubiquitinated receptors are brought back into the cell via the formation of pits, which burrow inwards from the plasma membrane. Upon ligand activation, many RTKs are found to localize to clathrin-coated pits \[[@B84-cells-08-01223],[@B85-cells-08-01223],[@B86-cells-08-01223]\]. Internalization can be blocked by chemical inhibitors of clathrin and small interfering RNAs (siRNA) against clathrin heavy chain. Such studies conclude clathrin-mediated endocytosis to be the predominant internalization route for this receptor family. Proteins that contain ubiquitin-interacting motifs (UIMs), such as epsin and Eps15, scaffold the receptor to components of the clathrin coat, e.g., AP-2 (appendage domain) as well as the terminal domain of clathrin heavy chain. In this way, clathrin coat components entrap their activated-RTK pit cargo. In the most well studied example, the EGFR--ligand complex can be detected in clathrin-coated vesicles 2--5 min after EGF stimulation \[[@B87-cells-08-01223],[@B88-cells-08-01223],[@B89-cells-08-01223],[@B90-cells-08-01223]\]. Rate elucidation studies have demonstrated that clathrin-mediated endocytosis is the fastest pathway but can become saturated if a large number of receptors are activated. In such cases, a slower clathrin-independent endocytosis contributes significantly \[[@B91-cells-08-01223]\]. This is evidenced in that siRNA against clathrin considerably impairs EGFR internalization only when low EGF is used \[[@B92-cells-08-01223]\]. Similar domains and pathway compensations were then reported for both the IR and the IGF-1R \[[@B79-cells-08-01223],[@B93-cells-08-01223],[@B94-cells-08-01223]\]. Clathrin-independent pathways are of two main types; early studies described a macropinocytosis-like process involving actin cytoskeletal rearrangements and membrane ruffling \[[@B87-cells-08-01223]\]. It is worth noting that studies have shown IGF-1R modulation by elements of the adhesion-associated protein complexes, including the discoidin domain receptor 1 (DDR1) \[[@B95-cells-08-01223]\], a non-integrin collagen RTK, and the non-receptor tyrosine adhesion kinase FES-related (FER) \[[@B96-cells-08-01223]\], meaning that the extracellular matrix and the adhesion signaling also contribute to IGF-1R subcellular trafficking. The second route is defined through its sensitivity to inhibitors of caveolae and cholesterol-disrupting agents \[[@B79-cells-08-01223],[@B92-cells-08-01223],[@B97-cells-08-01223]\]. Confocal microscopy with immuno-fluorescent localization demonstrates that the IGF-1R can localize with both the lipid raft caveolar marker tyrosine phospho-caveolin-1 (pY14) and also the early endosome marker EEA-1, meaning it can be internalized via both clathrin-dependent or clathrin-independent (caveolar) routes \[[@B79-cells-08-01223]\]. Aligning with context-dependent ligase recruitment, co-localization of the IGF-1R with phospho-caveolin occurs at high IGF-1 doses (100 ng/mL) and is enhanced by c-Cbl overexpression and decreased by Mdm2 overexpression. On the other hand, IGF-1R/clathrin co-localization occurs at low IGF-1 (5 ng/mL) doses and is enhanced by Mdm2 overexpression and inhibited by c-Cbl overexpression \[[@B79-cells-08-01223]\]. One possible scenario is sequential ligase action, with Mdm2 predominance at physiological ligand concentrations followed by c-Cbl at higher ligand concentrations that saturate the clathrin-dependent internalization route \[[@B69-cells-08-01223],[@B79-cells-08-01223]\]. This plethora of E3 ligases and receptor processing ultimately ensures flexibility to IGF-1R function for specific cellular needs.

After internalization of the receptor--ligand complex, the next steps involve the turnover of components. Using selective inhibitors and mutational studies, the sorting mechanisms begin to be pieced together. Members of all RTK subfamilies undergo this agonist-triggered accelerated lysosomal/proteasomal degradation, and therefore ligand-dependent global receptor downregulation is a hallmark of this receptor family. Overall, a lysosomal inhibitor has a much greater impact on wild-type IGF-1R degradation than a proteasome inhibitor, indicating that the IGF-1R is predominantly degraded through the lysosome and less by proteosomal action. It is, of course, feasible that part of the receptor is degraded via the proteasome and part is degraded lysosomaly. ATP-deficient mutants are not degraded at all, supporting the model of ligand-dependency and/or phosphorylation requirement \[[@B10-cells-08-01223],[@B69-cells-08-01223],[@B79-cells-08-01223]\]. In addition, the C-terminal tail of the receptor is a requirement for ubiquitination---a receptor that is functional in kinase activity but harbors a c-terminal tail truncation cannot be ubiquitinated \[[@B10-cells-08-01223],[@B69-cells-08-01223],[@B79-cells-08-01223],[@B81-cells-08-01223],[@B83-cells-08-01223],[@B98-cells-08-01223],[@B99-cells-08-01223]\]. Increasing the complexity of the system, ubiquitin-mediated control goes beyond the receptor to its docking station (e.g., IRS) and downstream signaling effectors \[[@B100-cells-08-01223]\]. The layers of regulation imposed upon the IGF-1R's intracellular journey by ubiquitination were recently extensively reviewed in \[[@B68-cells-08-01223]\].

2.3. Subcellular Receptor Trafficking {#sec2dot3-cells-08-01223}
-------------------------------------

Clathrin-dependent and -independent endocytosis both deliver receptor--ligand cargo to early endosomes located in the cell periphery. In most cases, the receptor--ligand complex remains intact, although the ligand can dissociate in the acidic environment of the endosome. In such cases, the released ligands are contained in the vesicular part of the endosome, whereas unoccupied receptors congregate in tubular extensions (membrane area) \[[@B63-cells-08-01223]\].

From this point, receptors can rapidly recycle back from early endosomes to the plasma membrane in a process known as back fusion. As the early endosome matures and moves towards the peri-centriolar region, its biochemical composition changes with increasing luminal acidification. The membrane invaginates inwards to create intra-luminal vesicles (ILVs), at which point the endosome is referred to as a multi-vesicular body (MVB) \[[@B101-cells-08-01223]\]. At this level, membrane invaginations have shifted the RTKs into the intra-luminal vesicles. If destined for recycling, RTKs can also be delivered to Rab11-containing recycling compartments; however, this is generally a slower route (30--60 min) than back fusion from earlier endosomes (2--5 min) \[[@B102-cells-08-01223]\]. As endosomal maturation continues, recycling cargo and early markers such as Rab5 and EEA1 are lost, and late endosomal markers such as Rab7 enrich \[[@B103-cells-08-01223]\]. Late endosomes fuse with primary lysosomes, and RTKs that reach this point are degraded by proteolytic enzymes. It is worth noting that many studies in this field do not dissociate recycling from degradation, and therefore reported rate alterations are likely composite images of changes in the relationship between the two intertwined. The specific contribution of receptor recycling on expression levels is rarely considered for the RTK family. However, one study does attribute considerable recycling to the IR system \[[@B104-cells-08-01223]\].

Another fate of the endocytosed RTK is the fusion of MVBs with the plasma membrane and the release of its contents as "exosomes". Discovered in the context of removal of the transferrin receptor \[[@B105-cells-08-01223]\] during maturation of reticulocytes and termed "selective externalization", this process has now been demonstrated for many physiological and pathological instances/cargo. Many RTKs have been reported to be released by cells in this way, including EGFR \[[@B106-cells-08-01223],[@B107-cells-08-01223],[@B108-cells-08-01223],[@B109-cells-08-01223]\], IGF-1R \[[@B110-cells-08-01223],[@B111-cells-08-01223]\], and MET \[[@B112-cells-08-01223]\]. The intricacies of how this mediates inter-cellular signaling and expands the signal profile of RTKs are just starting to be understood. Research has intensified in this area due to the discovery that cancer cells upregulate exosome production, and their cargo can have cancer-promoting effects on recipient cells. For example, exosomes released from melanoma cells that carry MET educate bone marrow progenitor cells towards a pro-metastatic phenotype \[[@B112-cells-08-01223]\].

RTKs and their endosomal sorting machinery were heavily investigated in close association with their kinase activity and due to their involvement in oncogenesis. Yet, over the last two decades, experimental, clinical, and epidemiological data clearly demonstrate that RTKs operate in a close relationship with the larger super-family of G protein-coupled receptors (GPCRs) in a wide range of physiological and pathological processes. The GPCR family has its own trafficking process orchestrated by the β-arrestin/G protein-coupled receptor kinase (GRK) system. The more knowledge we garner in this context demonstrates that the cross-talk between the two receptor systems goes beyond transactivation to the very heart of GPCRs' internalization machinery \[[@B10-cells-08-01223],[@B23-cells-08-01223],[@B113-cells-08-01223],[@B114-cells-08-01223],[@B115-cells-08-01223]\].

3. Receptor Internalization: The GPCR Route {#sec3-cells-08-01223}
===========================================

GPCRs, also known as 7 transmembrane domain receptors, comprise the largest family of cell surface receptors in mammalian cells. They are functionally much more diverse than the RTKs, spanning nearly every physiological process in the human body from nerve transmission to hormone signaling \[[@B116-cells-08-01223],[@B117-cells-08-01223]\]. As evidence to their critical roles in controlling physiological and pathological processes, at least a third of the drugs approved within the last decades target GPCRs \[[@B116-cells-08-01223],[@B118-cells-08-01223],[@B119-cells-08-01223],[@B120-cells-08-01223]\]. Yet, in spite of their dominance in the drug discovery field, a rather small fraction have anti-neoplastic indications---only 4.4% of the drugs on the market (21/475 in 2017) and 7.1% of the agents presently investigated in clinical trials (23/321 in 2017) \[[@B116-cells-08-01223]\]. They receive relatively minor attention when compared to the small-scale family of RTKs, of which targeting agents with cancer indications are approved every year. For instance, in 2015, there were 21 approved drugs only in the category of small molecule tyrosine kinase inhibitors, while many more were evaluated in advanced-phase clinical trials \[[@B121-cells-08-01223]\]. The number of studies assigning GPCR roles in oncogenesis is growing rapidly in recent years; therefore, it may be reasonable to claim that GPCRs' current position in anti-cancer drug development is just the tip of the iceberg and that their therapeutic potential is narrowly exploited.

Despite the staggering diversity of extracellular signals that they respond to, mechanistically, GPCRs share remarkably similar machinery for signaling activation and receptor trafficking \[[@B11-cells-08-01223],[@B113-cells-08-01223],[@B114-cells-08-01223],[@B122-cells-08-01223],[@B123-cells-08-01223]\]. The classical paradigm ([Figure 1](#cells-08-01223-f001){ref-type="fig"}A) describes GPCRs carrying out a six-phase functional journey, including G protein signaling activation and GRK-dependent phosphorylation of serine residues of the receptor, which triggers β-arrestin recruitment with subsequent receptor desensitization, internalization/trafficking, and a second signaling wave \[[@B11-cells-08-01223],[@B81-cells-08-01223],[@B124-cells-08-01223],[@B125-cells-08-01223],[@B126-cells-08-01223],[@B127-cells-08-01223]\].

3.1. G Protein Signaling {#sec3dot1-cells-08-01223}
------------------------

Unlike RTKs, GPCRs lack intrinsic catalytic activity and therefore rely on the interaction with their namesake G proteins for signaling activation. Ligand-binding to the GPCR induces conformational change within the receptor that promotes the coupling of heterotrimeric G proteins. The active receptor catalyzes the exchange of GDP to GTP on the G protein α subunit ([Figure 1](#cells-08-01223-f001){ref-type="fig"}A) \[[@B128-cells-08-01223]\]. The heterotrimeric G proteins use this additional energy to dissociate into Gα and Gβγ subunits \[[@B129-cells-08-01223]\], thus triggering the classical "G protein signaling pathway". Both effectors interact with downstream proteins to initiate several signaling branches, including the mitogen-activated protein kinase (MAPK) cascade, cyclic adenosine monophosphate (cAMP), Phosphoinositide 3-kinase (PI3K)-Akt, and protein kinase A (PKA) ([Figure 1](#cells-08-01223-f001){ref-type="fig"}A) \[[@B127-cells-08-01223],[@B130-cells-08-01223]\]. This activity continues until the system initiates negative feedback to turn off signaling (G protein desensitization). One such feedback determinant, increased Gβγ concentration, triggers GRKs recruitment to the vicinity of the activated receptor, commencing the "turning off" process. G protein desensitization occurs because the GRK-mediated phosphorylation event promotes the enrollment of a family of proteins known as β-arrestins to the receptor, which physically interrupt the receptor-G protein coupling \[[@B123-cells-08-01223],[@B131-cells-08-01223]\].

3.2. GRK/β-arrestin-Dependent Receptor Desensitization {#sec3dot2-cells-08-01223}
------------------------------------------------------

The first GRK isoforms were discovered almost half a century ago, when proteins capable of desensitizing the rhodopsin photoreceptor and the β2-adrenergic receptor via phosphorylation were identified \[[@B132-cells-08-01223],[@B133-cells-08-01223],[@B134-cells-08-01223],[@B135-cells-08-01223]\]. The human genome encodes seven GRK isoforms (GRK1--GRK7); GRK2/3/5/6 are ubiquitously expressed in all tissues, while GRK1/4/7 show specific expression \[[@B136-cells-08-01223]\]. All isoforms phosphorylate unique serine and threonine residues of the intracellular domains (third cytoplasmic loop) and/or the C-termini of activated receptors \[[@B131-cells-08-01223],[@B137-cells-08-01223]\]. GRKs' kinase domain active structure is stabilized by the docking interaction with the agonist-coupled GPCRs, and thus the phosphorylation of the substrates commences \[[@B138-cells-08-01223],[@B139-cells-08-01223]\]. Based on their structural resemblance, the GRKs are grouped into three subfamilies \[[@B140-cells-08-01223]\]. The GRK1 family includes GRK1 and 7, prenylated at their C-termini to enable their membrane localization \[[@B139-cells-08-01223],[@B141-cells-08-01223]\]. The GRK2 family includes GRK2 and 3, which display cytoplasmic localization and translocate to the membrane following association with heterotrimeric G protein βγ-subunits released upon receptor activation of G proteins \[[@B142-cells-08-01223],[@B143-cells-08-01223]\]. Members of the GRK2 family share approximately 84% sequence similarity, containing a pleckstrin homology (PH) domain, which controls G protein mediated translocation \[[@B129-cells-08-01223],[@B144-cells-08-01223],[@B145-cells-08-01223]\]. The GRK4 family comprises isoforms 4, 5, and 6 positioned at the plasma membrane due to their ability for direct PIP2 binding \[[@B146-cells-08-01223]\]. Unlike other members of the GRK family, GRK5 and GRK6 can phosphorylate both active and inactive receptors \[[@B139-cells-08-01223],[@B143-cells-08-01223]\]. All GRK-mediated phosphorylation engages the second major component of the system---a family of proteins named arrestins, as they were originally discovered to cease or "arrest" the G protein signaling \[[@B129-cells-08-01223],[@B147-cells-08-01223]\].

There are four isoforms of arrestins (1--4) encoded in the human genome; arrestins 1 and 4 are solely expressed in the retinal tissue, while arrestins 2 and 3 (also known as β-arrestins 1 and 2, respectively) are ubiquitously expressed in all tissues \[[@B148-cells-08-01223]\]. Although β-arrestins 1 and 2 have a largely similar structure and can partially substitute for each other in knock-out mouse models \[[@B149-cells-08-01223],[@B150-cells-08-01223]\], they can play similar, distinctive, or opposite roles in the regulation of GPCRs \[[@B151-cells-08-01223],[@B152-cells-08-01223],[@B153-cells-08-01223]\]. The GRK-dependent phosphorylation regulation of arrestin recruitment gave rise to the development of a "barcode hypothesis" \[[@B125-cells-08-01223],[@B136-cells-08-01223]\]. By translating a specific receptor conformation into patterns of β-arrestin recruitment and interaction, GRKs are said to establish a barcode across serine and threonine residues on the C-terminal tail, thus regulating receptor functionality \[[@B154-cells-08-01223],[@B155-cells-08-01223]\]. The two-step GPCR desensitization hypothesis whereby a family of Ser-Thr protein kinases (GRKs) specifically phosphorylate ligand-activated GPCRs, creating binding sites for arrestins to prevent further G protein recruitment, is termed heterologous desensitization ([Figure 1](#cells-08-01223-f001){ref-type="fig"}A) \[[@B126-cells-08-01223],[@B127-cells-08-01223],[@B129-cells-08-01223],[@B154-cells-08-01223],[@B156-cells-08-01223],[@B157-cells-08-01223],[@B158-cells-08-01223],[@B159-cells-08-01223],[@B160-cells-08-01223]\].

3.3. Receptor Internalization, Trafficking, and Second-Wave Signaling {#sec3dot3-cells-08-01223}
---------------------------------------------------------------------

Once recruited to the transmembrane docking site, β-arrestins block the coupling sites for the G proteins, bringing their signaling to an end \[[@B123-cells-08-01223],[@B131-cells-08-01223]\]. The desensitized receptor is internalized, which can lead to either recycling of the receptors to the plasma membrane or degradation. The wide repertoire of isoforms of the GRK/arrestin families allows for a spectrum of potential patterns (barcodes), which translate into distinct fates for the receptor complex \[[@B123-cells-08-01223],[@B129-cells-08-01223],[@B131-cells-08-01223],[@B155-cells-08-01223]\].

β-arrestins promote GPCR endocytosis by mediating an interaction between the C-terminus and the heavy chain of clathrin and β-subunit of adaptor protein-2 (AP2) \[[@B139-cells-08-01223],[@B161-cells-08-01223]\]. In much the same way as described earlier for RTKs, GPCRs are then concentrated in clathrin-coated pits, internalized, and finally follow steps in accordance with the isoform of β-arrestins employed in the downregulation. Although discovered and named for their signal arresting role, it is now clear that this under-represents reality. In addition to interrupting the receptor-G protein coupling and impairing the G protein signaling, β-arrestins 1 and 2 themselves activate their own signaling pathways, such as MAPK, PI3K, and NF-κB cascades, by acting as scaffold proteins \[[@B162-cells-08-01223],[@B163-cells-08-01223],[@B164-cells-08-01223],[@B165-cells-08-01223],[@B166-cells-08-01223],[@B167-cells-08-01223]\]. Differential affinities for the β-arrestin isoforms separate GPCRs into two major classes. Class A members such as the dopamine D1A receptor, the μ-opioid receptor, and the β2 adrenergic receptor bind β-arrestin 2 with greater affinity than β-arrestin 1, recycle rapidly, and transiently activate MAPK. Class B members such as the angiotensin II type 1A receptor and the vasopressin V2 receptor bind both isoforms with equal affinity, recycle slowly, and sustain MAPK signaling \[[@B168-cells-08-01223],[@B169-cells-08-01223],[@B170-cells-08-01223],[@B171-cells-08-01223]\].

Despite original models, it is now clear that internalization of a receptor does not necessarily mean immediate cessation of all associated signaling. Ligand-mediated endocytosis is multi-functional; although endosomal acidic dissociation of the ligand--receptor complex can attenuate any signal originating from it, the endosome can also facilitate the interaction between the internalized receptor and the downstream signaling molecules \[[@B172-cells-08-01223],[@B173-cells-08-01223],[@B174-cells-08-01223]\], best illustrated by the case of the arrestins. As multi-functional adaptor molecules, arrestins govern GPCR physiology, but does their affiliation lie solely with this receptor family?

4. IGF-1R as an RTK/GPCR Functional Hybrid {#sec4-cells-08-01223}
==========================================

The work that identified Mdm2 as a novel E3 ubiquitin ligase for the IGF-1R \[[@B76-cells-08-01223],[@B175-cells-08-01223]\] shed light on remarkable parallels between this receptor and the larger (but believed to be separate) family of GPCRs. The adaptor molecule that brings Mdm2 to the ligand-activated IGF-1R was discovered to be the master regulator of GPCR biology, β-arrestin \[[@B81-cells-08-01223],[@B176-cells-08-01223]\]. This work showed that, similar to GPCRs, β-arrestins not only aid IGF-1R internalization but initiate their own second wave of signaling through the MAPK/ERK pathway ([Figure 1](#cells-08-01223-f001){ref-type="fig"}B). Intriguingly, β-arrestin-mediated ERK activation occurs even in conditions with tyrosine kinase domain inhibited or mutated versions of the IGF-1R \[[@B49-cells-08-01223],[@B81-cells-08-01223],[@B177-cells-08-01223]\]. This dual role of β-arrestin 1 in the case of IGF-1R downregulation and signaling activation was reminiscent of its role in the GPCR family; while internalizing the ligand-activated receptor, β-arrestins also activate the MAPK pathway \[[@B11-cells-08-01223],[@B68-cells-08-01223],[@B81-cells-08-01223],[@B178-cells-08-01223]\] ([Figure 1](#cells-08-01223-f001){ref-type="fig"}B). Functional antagonism has also been revealed in regard to β-arrestin isoforms at the IGF-1R. Both isoforms co-immunoprecipitate with IGF-1R; however, the ligand-occupied receptor has greater affinity for β-arrestin 1. This association lasts longer and sustains MAPK/ERK signaling \[[@B81-cells-08-01223],[@B98-cells-08-01223]\]. Conversely, β-arrestin 2 has greater affinity for the ligand-unoccupied receptor. This interaction is transient and can trigger receptor ubiquitination and degradation but without any signal activation \[[@B81-cells-08-01223],[@B98-cells-08-01223]\] ([Figure 1](#cells-08-01223-f001){ref-type="fig"}B).

Recognized as a universal mechanism of GPCR regulation, β-arrestins bind to the receptor following phosphorylation of specific serine residues by the G protein-coupled receptor kinases (GRKs). This warranted investigation into the mechanism of β-arrestin binding to the IGF-1R, which revealed that GRK-mediated receptor phosphorylation coordinates this process \[[@B124-cells-08-01223]\] ([Figure 1](#cells-08-01223-f001){ref-type="fig"}B). There seems to be contrasting roles between GRK2 and 6, whereby phosphorylation of serine residues on the receptor C-terminal tail by either isoform encodes a barcode for subcellular fate \[[@B124-cells-08-01223]\] ([Figure 1](#cells-08-01223-f001){ref-type="fig"}B). Specifically, GRK2 phosphorylation promotes transient β-arrestin 2 binding and predominance for receptor recycling, whereas GRK6 promotes a stable receptor/β-arrestin 1 interaction that leads to receptor complex degradation \[[@B124-cells-08-01223]\] ([Figure 1](#cells-08-01223-f001){ref-type="fig"}B). The body of work that uncovered this shared functionality also shed light on a new onco-relevant link between the IGF-1R and the crucial tumor suppressor, p53. Transcriptional links between the two pathways have been well established---wildtype but not mutant p53 suppresses IGF-1R gene transcription, part of the mechanism by which p53 can arrest the cell cycle \[[@B179-cells-08-01223],[@B180-cells-08-01223],[@B181-cells-08-01223]\]. The discovery of Mdm2/β-arrestin-mediated IGF-1R ubiquitination also exposed IGF-1R and p53 protein co-dependency, as they compete for the same E3 ligase, Mdm2 \[[@B76-cells-08-01223],[@B81-cells-08-01223],[@B175-cells-08-01223],[@B176-cells-08-01223]\]. Furthermore, by controlling the relative expression of the arrestin isoforms, we demonstrated knock-on effects on p53 levels. Imbalance towards the β-arrestin 1 isoform via overexpression or silencing of β-arrestin 2 sustains MAPK signaling and keeps p53 at basal low levels ([Figure 2](#cells-08-01223-f002){ref-type="fig"}C) \[[@B98-cells-08-01223],[@B99-cells-08-01223]\]. The opposing scenario---imbalance towards β-arrestin 2---circumvents MAPK signaling and causes p53 levels to accumulate ([Figure 2](#cells-08-01223-f002){ref-type="fig"}D), leading to cell cycle arrest and decreased viability of melanoma cells \[[@B98-cells-08-01223],[@B99-cells-08-01223]\]. This scenario does, however, require functional p53, highlighting an interesting therapeutic scenario in the group of wildtype p53 cancers \[[@B98-cells-08-01223],[@B99-cells-08-01223],[@B182-cells-08-01223]\].

Initially suggested by the peculiar sensitivity of the IGF-1R to the Gi protein inhibitor, pertussis toxin \[[@B114-cells-08-01223],[@B183-cells-08-01223]\], and having been fully explored by extensive studies since then, it is now clear that the IGF-1R makes direct use of all GPCR signaling components: G proteins, GRKs, and β-arrestins \[[@B11-cells-08-01223],[@B39-cells-08-01223],[@B68-cells-08-01223],[@B81-cells-08-01223],[@B98-cells-08-01223],[@B124-cells-08-01223],[@B176-cells-08-01223]\]. While examples of RTKs/GPGRs family crosstalk have been known for quite some time \[[@B15-cells-08-01223]\], this is distinct from that which can occur at the IGF-1R, whereby this receptor is directly utilizing GPCR components of G proteins, GRKs, and β-arrestins and can activate a signal cascade in a kinase domain-independent fashion. By all functional definitions, the IGF-1R has shown itself capable of classification as a functional GPCR. In respect of the evidence, we advocate that the IGF-1R should be regarded as an RTK/GPCR functional hybrid \[[@B10-cells-08-01223],[@B11-cells-08-01223],[@B23-cells-08-01223]\] and that this paradigm should be used for drug development. This is especially important, as targeting strategies designed under a kinase-only paradigm have already proven to be insufficient and thus outsmarted by this complex network.

5. Discussion: Therapeutic Implications {#sec5-cells-08-01223}
=======================================

Over the last few decades, the potential of IGF-1R as a target for cancer treatment has been extensively investigated and almost exclusively aligned to the kinase-fits-all model. Nevertheless, the critical role of receptor removal from the cell surface was openly recognized from the beginning, which was exemplified when Renato Baserga stated, in 2005, "An antibody against the IGF-IR, to be effective, has to inhibit the binding of both IGF-1 and IGF-2, induce the downregulation of the receptor, and have little or no effect on the IR signaling" \[[@B13-cells-08-01223]\]. This concept, fundamentally true for all anti-IGF-1R strategies, emerged from the early antisense-based experimental work, which described complete inhibition of cancer cells growing in monolayer or as xenografts in animal models \[[@B13-cells-08-01223]\]. The corollary of these studies is that preventing the receptor's de novo synthesis (e.g., antisense, siRNA) results in an overall decrease of IGF-1R expression and all of its signaling branches ([Figure 2](#cells-08-01223-f002){ref-type="fig"}). This process is similar to the one employed by the cells in basal conditions in that it diminishes the downstream signaling in a *balanced* manner ([Figure 2](#cells-08-01223-f002){ref-type="fig"}). In place of gene silencing (not yet possible in humans), kinase inhibitors or the antibodies-based strategy targeting IGF-1R are preferred in clinical settings. Just like anti-sense strategies, all antibodies and all kinase inhibitors against IGF-1R tested thus far in clinical trials ([Table 1](#cells-08-01223-t001){ref-type="table"}) were confirmed to preclude kinase-dependent signaling activation \[verified as decreased phosphorylated-(p-)IGF-1R\]. However, with the notable exception of picropodophyllin (PPP) \[[@B47-cells-08-01223],[@B48-cells-08-01223],[@B184-cells-08-01223],[@B185-cells-08-01223]\], all kinase inhibitors had no effects on IGF-1R expression at the cell surface ([Table 1](#cells-08-01223-t001){ref-type="table"}). It is worth mentioning that, in the case of kinase inhibitors, both pERK and pAkt were employed to verify the inhibition of downstream signaling, and they were found to be decreased in a balanced manner ([Table 1](#cells-08-01223-t001){ref-type="table"}). Once more, PPP was the exception, demonstrating biased pERK activation linked to the downregulation process \[[@B49-cells-08-01223]\]. On the other hand, when it came to targeting antibodies, pAkt was always employed as a surrogate to verify decreased downstream IGF-1R signaling, whereas pERK was found to be reduced, increased, or was not investigated ([Table 1](#cells-08-01223-t001){ref-type="table"}). Follow up studies confirmed pAkt inhibition but discovered that pERK, in different experimental models, demonstrated a great degree of variability ([Table 1](#cells-08-01223-t001){ref-type="table"}).

Intriguingly, in contradiction with the classical paradigm postulating kinase activity/downregulation interdependency, all antibodies proved very effective at downregulating the IGF-1R ([Table 1](#cells-08-01223-t001){ref-type="table"}). This process occurred very fast in cell lines models (1--4 h) and was also confirmed in xenografts models ([Table 1](#cells-08-01223-t001){ref-type="table"}), yet the clinical results are far from what was expected. We and others demonstrated that antibody-induced IGF-1R downregulation stabilizes a *biased* receptor conformation that preferentially activates kinase-independent β-arrestin 1 signaling ([Figure 2](#cells-08-01223-f002){ref-type="fig"} and [Table 1](#cells-08-01223-t001){ref-type="table"}) and not only promotes MAPK enhancement but also represses the tumor suppressor p53 activation ([Figure 2](#cells-08-01223-f002){ref-type="fig"}), which could explain the cancer cell survival, the augmented metastatic potential, and the overall limited response to this single agent therapy \[[@B10-cells-08-01223],[@B39-cells-08-01223],[@B98-cells-08-01223],[@B99-cells-08-01223],[@B182-cells-08-01223]\]. It should be noted here that there were some exceptions \[[@B186-cells-08-01223]\]. Firstly, most antibodies do show response in in vivo models, and secondly, clinical response to single-agent anti-IGF-1R is reported in some patients, particularly in Ewing's sarcoma. A number of reasons are suggested for this unique efficacy, including that it derives from their genetic hallmark: the direct connection between their oncogenic fusion EWS/ETS transcripts and the IGF system \[[@B34-cells-08-01223],[@B187-cells-08-01223],[@B188-cells-08-01223],[@B189-cells-08-01223]\]. In such cases, the aberrant EWS/ETS transcript likely influences IGF signaling to such a degree that the impact of an antibody shifts the balance differently than the norm. Whilst hoping that these few success cases could offer important insight into the mechanisms, anti-IGF-1R therapy is still yet to reach clinical practice in the treatment of Ewing's sarcoma patients, nor any other cancer types \[[@B190-cells-08-01223]\]. The prerequisite for efficient targeting of receptor removal set against the reality that its downregulation triggers signaling sustaining the cancer-phenotype presents a problem with no apparent way out. However, a possible solution was revealed by studies demonstrating the molecular mechanism behind arrestin involvement, i.e., opposing behaviors of the β-arrestin isoforms on IGF-1R downregulation and signaling \[[@B98-cells-08-01223]\]. Both β-arrestins downregulate the receptor, however, β-arrestin 2 is more efficient in conditions with low ligand availability. Most importantly, such conditions promote a GPCR class A-like behavior of the IGF-1R with transient β-arrestin 2/receptor interaction and subsequent MAPK-biased signaling and eventually with p53 reactivation ([Figure 2](#cells-08-01223-f002){ref-type="fig"}) \[[@B98-cells-08-01223],[@B99-cells-08-01223],[@B182-cells-08-01223]\]. While uncovering antagonism between the β-arrestin isoforms in controlling IGF-1R downregulation, it was demonstrated that biasing the IGF system toward β-arrestin 2 decreases the viability and the metastatic potential of cancer cells and hence could be considered an effective therapeutic strategy ([Figure 2](#cells-08-01223-f002){ref-type="fig"}) \[[@B98-cells-08-01223],[@B99-cells-08-01223],[@B182-cells-08-01223]\]. As β-arrestin 2 is more efficient in downregulating the receptor in conditions with low ligand, another option could be to develop therapeutic strategies involving ligand sequestration (e.g., anti-IGF antibodies or IGF traps) whilst also tipping the arrestin balance toward β-arrestin 2.

It could be argued that destabilizing the β-arrestin 1/β-arrestin 2 equilibrium via transgenic approaches encounters the same limitations as transgenic downregulation of the IGF-1R. Then again, we have to consider the fact that Mdm2 co-orchestrates stress-induced survival pathways by acting as ubiquitin ligase for IGF-1R, p53 and β-arrestins. Within this scenario, we recently demonstrated that disruption of the Mdm2--p53 interaction by small molecule Nutlin-3 allows Mdm2 accumulation and triggers IGF-1R/Mdm2 association with subsequent receptor ubiquitination and downregulation \[[@B99-cells-08-01223]\]. Under such conditions, the MAPK signaling associated with receptor downregulation is biased towards βarrestin 2, is transient and not sufficient to provide protection for malignant cells ([Figure 2](#cells-08-01223-f002){ref-type="fig"}) \[[@B98-cells-08-01223],[@B99-cells-08-01223],[@B182-cells-08-01223]\]. Add all of this to the reactivation of p53 and the possibility to control the β-arrestin recruitment via the GRK system and a comprehensive anti-tumorigenic cellular scenario arises.

6. Concluding Remarks {#sec6-cells-08-01223}
=====================

The central roles in cancer of RTKs in general and IGF-1R in particular have been known for many decades, and they serve as targets for many therapeutic approaches. In the post-trial years, various reasons have been suggested for the failure of first-line strategies, most highlighting the unappreciated complexity of the IGF-1R/IR system: including multiple ligands, hybrid receptors between the IGF-1R and the IR, nuclear translocation of components, cross-talk to other pathways, as well as a lack of patient selection markers, reasons which have been reviewed extensively elsewhere \[[@B17-cells-08-01223],[@B18-cells-08-01223],[@B22-cells-08-01223],[@B190-cells-08-01223],[@B191-cells-08-01223],[@B192-cells-08-01223],[@B193-cells-08-01223],[@B194-cells-08-01223]\]. This review focuses on the IGF-1 and IGF-1R path due to its intense study in drug development pipelines, however, this is not intended to reflect the importance of IGF-2 or IGF-2R. IGF-2 is by far the most abundant peptide from the IIGF family in human circulation. Considering its much more limited study, it is reasonable to claim that we are vastly under-informed on the specific contribution of this arm to patho-physiology. This perspective is comprehensively reviewed by Holly et al. within this special focus issue \[[@B195-cells-08-01223]\].

All the while, the traditional kinase-only model of activation is still prevalent in drug development. With this review, we aim to draw a parallel with the more successful story of GPCR targeting, where the naive ON/OFF model was abandoned more than a decade ago. For RTKs in general and IGF-1R in particular, in addition to the classical kinase signaling, their ultimate biological effects are orchestrated by several other post-translational modifications, interactions, and biological processes. It is now clear that the endosome is deeply entrenched in growth factor receptor function. Defective vesicular trafficking of growth factor receptors, including an imbalance between recycling versus degradation and versus exosomal release, appears prevalent. Derailed endocytosis is thus emerging as a multi-factorial hallmark of cancer cells \[[@B196-cells-08-01223]\]. There is now a critical need for a widespread update to the working model that recognizes the intricacies of the IGF signaling system; only then will rational drug design, therapeutic combinations, and real clinical benefits match the decades of supportive experimental data in the field.
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![IGF-1R as a receptor tyrosine kinase (RTK)/G protein-coupled receptors (GPCR) functional hybrid model. (**A**) Classical mechanism of signaling activation and receptor trafficking of GPCRs: (1) Ligand-binding induced receptor activation leads to GDP exchange for GTP on the G protein α subunit, resulting in the dissociation into Gα and Gβγ subunits. G protein subunits then interact with second effector proteins to promote several downstream pathways. (2) The increased concentration of Gβγ subunits initiates G protein-coupled receptor kinase (GRK) recruitment. (3) GRKs phosphorylate the receptor at c-terminal serine/threonine residues, recruiting β-arrestins. (4) β-arrestins bind to the phosphorylated receptor, preventing G protein coupling and impeding further G protein signaling. (5) The receptor becomes desensitized and is internalized and trafficked through recycling or degradation pathways. (6) By acting as a scaffold, β-arrestin initiates a second wave of downstream signaling \[mitogen-activated protein kinase (MAPK) is illustrated\]. (**B**) IGF-1R shares GPCR functionality in signaling and trafficking: (1) The ligand-activated IGF-1R facilitates G protein subunit dissociation and subsequent downstream G protein signaling. In parallel, receptor autophosphorylation activates classical kinase signaling. (2) GRKs phosphorylate the receptor at C terminal serine residues. (3) β-arrestins are recruited, which (4) prevents further G protein coupling and initiates the desensitization and the internalization of the receptor. (5) Once internalized, the receptor is directed for recycling or degradation. (6) β-arrestins control the activation of secondary wave of kinase-independent signaling.](cells-08-01223-g001){#cells-08-01223-f001}

![Therapeutic implications for IGF-1R downregulation as related to various types of associated signaling activation. (**A**) Balanced signaling: IGF-1 (balanced agonist) binds to the receptor and equally activates all downstream signaling in a balanced manner---G protein, kinase, and β-arrestin 1/β-arrestin 2 signaling (β-1/β-2). Receptors can then be either degraded or recycled. This results in moderate intensity pERK and basal p53 levels. (**B**) Balanced inhibition: small interfering RNAs (siRNA)/short hairpin RNAs (shRNA)-mediated IGF-1R depletion results in inhibition of all downstream signaling. This strategy diminishes pERK and slightly elevates p53 levels. (**C**) β-Arrestin 1 biased signaling: Anti-IGF-1R antibodies \[Figitumumab, also known as CP-751871 (CP in the Figure)\] treatment results in receptor degradation with β-arrestin 1-biased signaling and sustained pERK activity, and β-arrestin 1 signaling predominance maintains low p53 levels. (**D**) β-Arrestin 2 biased signaling (β-arrestin 2 overexpression/β-arrestin 1 inhibition): the receptor preferentially binds β-arrestin 2, generating a transient pERK signal and receptor recycling. β-arrestin 2 signaling (or absence of β-arrestin 1 signaling) increases p53 levels, possibly by sequestering both β-arrestin 1 and Mdm2 in the cytoplasm. (**E**) β-Arrestin2 biased signaling (Nutlin-3 treatment): small molecule Nutlin-3, a promising therapeutic option, activates transient ERK signaling and produces a boost of p53, mimicking the pattern observed upon β-arrestin 2 overexpression.](cells-08-01223-g002){#cells-08-01223-f002}

cells-08-01223-t001_Table 1

###### 

Effect of IGF-1R targeting on receptor signaling and downregulation.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Compound                           IGF-1R Downstream Signaling   IGF-1R\                       β-arr\                                                                                                                                                                                      
                                                                   Downregulation                Signaling                                                                                                                                                                                   
  ---------------------------------- ----------------------------- ----------------------------- --------------------------------------------------- ----------------------------- --------------------------------------------------- ----------------------------------------------------- ----------------------------------
  **IGF-1R Monoclonal Antibodies**                                                                                                                                                                                                                                                           

  Cixutumumab\                       ↓ \[[@B20-cells-08-01223]\]   ↓ \[[@B20-cells-08-01223]\]                                                       ↓ \[[@B20-cells-08-01223]\]   ↓ \[[@B26-cells-08-01223]\]                         Yes \[[@B20-cells-08-01223]\]                         
  (IMC-A12)                                                                                                                                                                                                                                                                                  

  Teprotumumab\                      ↓ \[[@B21-cells-08-01223]\]   ↓ \[[@B21-cells-08-01223]\]                                                       → \[[@B21-cells-08-01223]\]   ↑ \[[@B27-cells-08-01223]\]                         Yes \[[@B21-cells-08-01223]\]                         β-arr1 \[[@B27-cells-08-01223]\]
  (R1507)                                                                                                                                                                                                                                                                                    

  Dalotuzumab\                       ↓ \[[@B28-cells-08-01223]\]   NI                            ↓ \[[@B29-cells-08-01223],[@B30-cells-08-01223]\]   NI                            → \[[@B30-cells-08-01223],[@B31-cells-08-01223]\]   Yes \[[@B28-cells-08-01223],[@B30-cells-08-01223]\]   
  (MK-0646)                                                                                                                                                                                                                                                                                  

  Ganitumab\                         ↓ \[[@B32-cells-08-01223]\]   ↓ \[[@B32-cells-08-01223]\]                                                       NI                            → \[[@B33-cells-08-01223]\]                         Yes \[[@B32-cells-08-01223]\]                         
  (AMG 479)                                                                                                                                                                                                                                                                                  

  Robatumumab\                       ↓ \[[@B34-cells-08-01223]\]   ↓ \[[@B34-cells-08-01223]\]                                                       ↓ \[[@B34-cells-08-01223]\]   ↓ \[[@B35-cells-08-01223]\]                         Yes \[[@B34-cells-08-01223]\]                         
  (SCH717454)                                                                                                                                                                                                                                                                                

  AVE1642\                           ↓ \[[@B36-cells-08-01223]\]   ↓ \[[@B36-cells-08-01223]\]                                                       ↓ \[[@B36-cells-08-01223]\]   → \[[@B37-cells-08-01223]\]                         Yes \[[@B36-cells-08-01223]\]                         
  (EM164)                                                                                                                                                                                                                                                                                    

  Figitumumab\                       ↓ \[[@B38-cells-08-01223]\]   ↓ \[[@B38-cells-08-01223]\]                                                       NI                            ↑ \[[@B39-cells-08-01223]\]\                        Yes \[[@B38-cells-08-01223]\]                         β-arr1 \[[@B39-cells-08-01223]\]
  (CP-751)                                                                                                                                                                         → \[[@B40-cells-08-01223]\]                                                                               

  αIR3                               ↓ \[[@B41-cells-08-01223]\]   NI                            ↓ \[[@B42-cells-08-01223]\]                         NI                            ↓ \[[@B43-cells-08-01223]\]\                        NI                                                    
                                                                                                                                                                                   ↑ \[[@B44-cells-08-01223]\]                                                                               

  **Tyrosine Kinase Inhibitors**                                                                                                                                                                                                                                                             

  BMS-536924                         ↓ \[[@B45-cells-08-01223]\]   ↓ \[[@B45-cells-08-01223]\]                                                       ↓ \[[@B45-cells-08-01223]\]                                                                                                             

  OSI-906\                           ↓ \[[@B2-cells-08-01223]\]    ↓ \[[@B2-cells-08-01223]\]                                                        ↓ \[[@B2-cells-08-01223]\]    ↓ \[[@B46-cells-08-01223]\]                         NI                                                    
  (linsitinib)                                                                                                                                                                                                                                                                               

  AXL1717\                           ↓ \[[@B47-cells-08-01223]\]   ↓ \[[@B47-cells-08-01223]\]                                                       ↓ \[[@B47-cells-08-01223]\]   ↓ \[[@B48-cells-08-01223]\]\                        Yes \[[@B50-cells-08-01223]\]                         β-arr \[[@B49-cells-08-01223]\]
  (PPP)                                                                                                                                                                            ↑ \[[@B49-cells-08-01223]\]                                                                               

  BMS-754807                         ↓ \[[@B51-cells-08-01223]\]   ↓ \[[@B51-cells-08-01223]\]                                                       ↓ \[[@B51-cells-08-01223]\]   ↓ \[[@B52-cells-08-01223]\]                         NI                                                    NI

  AG-1024\                           ↓ \[[@B53-cells-08-01223]\]   NI                            ↓ \[[@B54-cells-08-01223]\]                         NI                            ↓ \[[@B55-cells-08-01223]\]                         NI                                                    NI
  (Tyrphostin)                                                                                                                                                                                                                                                                               

  NVP-AEW541                         ↓ \[[@B56-cells-08-01223]\]   ↓ \[[@B56-cells-08-01223]\]                                                       ↓ \[[@B56-cells-08-01223]\]   ↓ \[[@B57-cells-08-01223],[@B58-cells-08-01223]\]   NI                                                    NI

  KW-2450                            ↓ \[[@B59-cells-08-01223]\]   ↓ \[[@B59-cells-08-01223]\]                                                       ↓ \[[@B59-cells-08-01223]\]                                                       NI                                                    NI
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NI: Not investigated; ↓: inhibition; ↑: activation; →: no changes; β-arr: β-arr signal.
